Magnetic gold nanohybrid particles will help fight cancer

Credit: Sergey Gnuskov/NUST MISIS

News • Theranostics

Magnetic gold nanohybrid particles will help fight cancer

A team of scientists at the Russian National University of Science and Technology MISiS, together with colleagues from Russia and Germany, have presented a detailed study of magnetite-gold nanohybrids.

In the future, such nanoparticles can help in theranostics — the diagnostics and subsequent therapy of oncological diseases. The results of the work have been published in the Journal of Materials Chemistry B.

Photo
Maxim Abakumov, head of the Biomedical Nanomaterials laboratory at NUST MISIS

Credit: Sergey Gnuskov/NUST MISIS

Magnetic resonance imaging is one of the most effective ways to detect cancer in the early stages. To increase its accuracy, a special contrast agent with magnetic properties can be injected into the patient’s body — with a special selection of parameters, the agent will ‘highlight’ the malignant cells,” says Maxim Abakumov, head of the Biomedical Nanomaterials laboratory at NUST MISIS. However, in addition to diagnostics, magnetic materials are promising for use in the treatment of oncological diseases. Under the high temperatures, magnetic nanoparticles can heat up and destroy the shell of cancer cells.“

The team from NUST MISIS has been developing magnetic nanoparticles for theranostics (a combination of diagnostics and therapy) based on magnetite (Fe3O4) for several years. Recently, the next stage of fundamental research has been completed. Together with the colleagues from Lomonosov Moscow State University, D. Mendeleev University of Chemical Technology of Russia, the Russian National Research Medical University and the University of Duisburg-Essen (Germany) scientists studied the formation of hybrid magnetite-gold nanoparticles. It is widely known that this precious metal is well accepted by the body; its role is to ensure the biocompatibility of the dimer (complex structure).

Photo
The liquid samples

Credit: Sergey Gnuskov/NUST MISIS

Scientists examined the nucleation, growth and faceting of magnetite-gold nanohybrids by taking liquid samples from the reaction mixture during the synthesis process. For this, X-ray phase analysis, transmission electron microscopy, and vibromagnetometry were used. “We observed two consecutive processes during the formation of magnetite. First, the growth of spherical magnetite nanoparticles on the surface of Au seeds at temperatures up to 220°C. Secondly, there is a gradual faceting of iron oxide nanoparticles to octahedrons at the boiling stage from 240 to 280°C with the constant volume of nanoparticles,” comments Ulf Widwald, research participant, associate professor at the University of Duisburg Essen. 

This is the most detailed analysis of the properties of the dimeric nanoparticles with magnetite preparation ever carried out. Scientists note that the data they obtained allow them to control the size and shape of nanoparticles due to the ability to control the chemical reaction parameters. In the future, this will help to scale up the production of theranostic nanoparticles to serial.


Source: National University of Science and Technology MISiS (NUST MISIS)

31.07.2020

Read all latest stories

Related articles

Photo

News • From nanotechnology

A better prognostic tool for brain cancer

A new nano-fabricated platform for observing brain cancer cells provides a much more detailed look at how the cells migrate and a more accurate post-surgery prognosis for brain cancer (glioblastoma)…

Photo

News • High-glade glioma research

Understanding why deadly brain cancer comes back

A surprising mechanism explains why high-grade gliomas, the deadliest form of brain cancer, returns: The tumours adapt to treatment by recruiting help from nearby healthy tissue.

Photo

News • Identification of treatment barriers

Immunotherapy: The right environment for fighting cancer

Cancer immunotherapy is a successful treatment form in oncology, but it doesn't work for every patient. One problem may be the lack of a specific type of immune cell in the tumor, researchers found.

Related products

Canon – Alphenix 4D CT

Multi-Modality Suites

Canon – Alphenix 4D CT

Canon Medical Systems Europe B.V.
Canon - Aquilion Exceed LB

Oncology CT

Canon - Aquilion Exceed LB

Canon Medical Systems Europe B.V.
Canon – Aquilion LB

Oncology CT

Canon – Aquilion LB

Canon Medical Systems Europe B.V.
Canon – Vitrea Advanced Visualization

Reading

Canon – Vitrea Advanced Visualization

Canon Medical Systems Europe B.V.
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Subscribe to Newsletter